All In Biotech

Drug Trial Radar · NCT05804526

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

An Open-label, Non-randomised, Multi-center Study to Evaluate the Safety, and Efficacy Off RC88 Combined With Sintilimab in AdvancedSolid Tumours

Last checked: Nov 19, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

82

Planned (sponsor's estimate)

Start

Jul 19, 2023

Primary completion

May 2025

Study completion Dec 2025

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate safety , clinical pharmacology and efficacy of intravenous RC88 combined with Sintilimab in advancedsolid tumours

Conditions

  • Advanced Solid Tumours

Interventions

  • RC88Drug

    1.5mg/kg ,2.0mg/kg ,2.5mg/kg by intravenous (IV) infusion,every 3 weeks

  • Sintilimab InjectionDrug

    Sintilimab 200mg by intravenous (IV) infusion,every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2DTime frame: 28 days after first treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.